Centre Hospitalier De Saint-Quentin
- Address
- lock Available on a paid plan
Neoplasms in Pneumology Research
At Centre Hospitalier De Saint-Quentin, clinical research in the neoplasms area focuses on advanced prostate cancer, especially metastatic castration-resistant prostate cancer. These studies are designed to assess whether new treatment combinations can improve survival and delay disease progression.
- Evaluating a new therapy approach for advanced prostate cancer
- Measuring impact on overall survival and disease control
- Exploring better treatment effectiveness for patients with resistant disease
This work reflects a strong interest in improving outcomes for hard-to-treat cancer, with a clear focus on treatment benefit and long-term disease management.
Bacterial Infections and Mycoses Research in Respiratory Disease
The site also studies bacterial infections affecting the lungs, with attention to Mycobacterium xenopi pulmonary infection. This research aims to determine whether adding a targeted inhaled treatment can improve infection clearance compared with standard care alone.
- Studying a lung infection caused by Mycobacterium xenopi
- Assessing improvement in sputum conversion and infection control
- Testing whether an added therapy can strengthen standard treatment
Through this infectious disease program, Saint Quentin contributes to efforts that may improve diagnosis-related outcomes and treatment success for difficult pulmonary infections.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 87 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 65 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier De Saint-Quentin
lock Showing 1 of 33 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Aug 2019 | Aug 2025 |
IMP list
lock Showing 1 of 87 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 10 | Unknown | 2015-11-20 | 2025-10-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.